AdvisorShares Trust AdvisorShares Pure US Cannabis ETF (ARCA: MSOS)

Dernières nouvelles pour AdvisorShares Trust AdvisorShares Pure US Cannabis ETF (ARCA:MSOS)

Healthcare

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from the marijuana and hemp business in the United States and in derivatives that have economic characteristics similar to such securities. It will concentrate at least 25% of its investments in the pharmaceuticals, biotechnology and life sciences industry group within the health care sector. The fund is non-diversified.

Curaleaf Holdings Inc.

Blackrock Treasury Trust

Drey Inst Pref Gov Mm-M

Blackrock Treasury Trust Instl 62

AdvisorShares Pure US Cannabis ETF

AdvisorShares Trust AdvisorShares Pure US Cannabis ETF

Goldman Sachs analyst James Schneider initiates coverage on Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy rating and announces Price Target of $285.

News

Price Target

Initiation

Analyst Ratings

Goldman Sachs Initiates Coverage On Analog Devices with Buy Rating, Announces Price Target of $285

Goldman Sachs analyst James Schneider initiates coverage on Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy rating and announces Price Target of $88.

MCHP

Goldman Sachs Initiates Coverage On Microchip Technology with Buy Rating, Announces Price Target of $88

RBC Capital analyst Arun Viswanathan maintains FMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) with a Sector Perform and raises the price target from $40 to $47.

RBC Capital Maintains Sector Perform on FMC, Raises Price Target to $47

RBC Capital analyst Arun Viswanathan maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Outperform and raises the price target from $74 to $85.

CTVA

RBC Capital Maintains Outperform on Corteva, Raises Price Target to $85

Goldman Sachs analyst James Schneider initiates coverage on Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Buy rating and announces Price Target of $225.

Goldman Sachs Initiates Coverage On Texas Instruments with Buy Rating, Announces Price Target of $225

<a href="https://d1io3yog0oux5.cloudfront.net/_cc809716af22826d6b497dbdf8d85863/omegahealthcare/db/2905/27976/pdf/Omega+Healthcare+-+New+Investor+Presentation+-+July+10+2025+v1.pdf" title="https://d1io3yog0oux5.cloudfront.net/_cc809716af22826d6b497dbdf8d85863/omegahealthcare/db/2905/27976/pdf/Omega+Healthcare+-+New+Investor+Presentation+-+July+10+2025+v1.pdf">https://d1io3yog0oux5.cloudfront.net/_cc809716af22826d6b497dbdf8d85863/omegahealthcare/db/2905/27976/pdf/Omega+Healthcare+-+New+Investor+Presentation+-+July+10+2025+v1.pdf</a>

Guidance

Omega Healthcare Investors Issues 2025 July Investor Presentation

WIIM

K Wave Media shares are trading higher after the company announced it has secured a $1 billion capacity to drive its Bitcoin treasury strategy. Additionally, the company has raised $500 million through a convertible note agreement.

Goldman Sachs analyst James Schneider initiates coverage on Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Neutral rating and announces Price Target of $75.

MRVL

Goldman Sachs Initiates Coverage On Marvell Tech with Neutral Rating, Announces Price Target of $75

DeFi Development Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) (the "Company") the first public company with a treasury strategy built to accumulate and compound Solana ("SOL"), announced today the purchase of 153,225 Solana ("SOL") at an average purchase price of $154.85 and valued at approximately $23.72 million. Following this transaction, DeFi Dev Corp. now holds approximately 846,630 SOL and SOL equivalents, including staking rewards, making the Company the largest Solana treasury company, by both total holdings and market capitalization.
The latest purchase was funded, in part, by $9.65 million in net proceeds from the exercise of the greenshoe option tied to the Company's previously announced convertible note offering. Below is a summary of DeFi Dev Corp.'s current SOL position and key per-share metrics as of July 10, 2025:
<ul>
<li>Total SOL &amp; SOL Equivalents Held: 846,630</li>
<li>Total SOL &amp; SOL Equivalents Held (USD): approximately $133.1 million</li>
<li>Total Shares Outstanding: 18,577,134</li>
<li>SOL per Share ("SPS"): 0.0456</li>
<li>SPS (USD): $7.16</li>
</ul>
Shares outstanding are as of July 9, 2025. The most recently purchased SOL will be held long-term and staked to a variety of validators, including DeFi Dev Corp.'s own Solana validators to generate native yield.
The Company will continue to provide suitable updates to our Treasury and underlying strategies, through public releases and regulatory filing(s), as available. &nbsp;

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

DFDV

DeFi Dev Corp. Buys 153,225 SOL For ~$23.72M, Bringing Total Holdings To 846,630 SOL

Goldman Sachs analyst James Schneider initiates coverage on ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Neutral rating and announces Price Target of $160.

Goldman Sachs Initiates Coverage On ARM Holdings with Neutral Rating, Announces Price Target of $160

The Cato Institute and the New Civil Liberties Alliance (NCLA) have called on the Federal Circuit to strike down President Donald Trump&#8216;s tariffs, arguing they rely on a statute that does not grant any authority to impose such tariffs.
What Happened:&nbsp;According to briefs filed by the Cato Institute and the NCLA, the International Emergency Economic Powers&nbsp;Act (IEEPA) does not give the president authority to impose tariffs, Reason <a href="https://reason.com/2025/07/09/appeals-court-briefs-say-trumps-tariffs-are-based-on-a-statute-that-does-not-authorize-tariffs-at-all/">reported</a>. They argue that the Constitution grants that power exclusively to Congress.
The CIT's decision in VOS Selections v. Trump concluded that neither set of tariffs—intended to curb drug trafficking and reduce trade deficits—was authorized under the IEEPA. The Trump administration is now challenging the ruling through an appeal.
In two briefs filed on Tuesday, the Cato Institute and NCLA contend that the CIT should have taken a broader stance by declaring that the IEEPA does not authorize tariffs &#8220;at all.&#8221;
The CIT ruling addressed two categories of tariffs: duties on imports from China, Mexico, and Canada, and the &#8220;Liberation Day&#8221; tariffs affecting goods from nearly all nations. In both instances, Trump cited an &#8220;unusual and extraordinary threat&#8221; and declared a &#8220;national emergency&#8221; under the IEEA to justify the measures.
Both Cato and the NCLA maintain that the statute does not grant the president &#8220;an unbounded tariff authority.&#8221; In their Federal Circuit briefs, they argue that the IEAA provides no tariff authority to the president at all. &#8220;The Constitution vests the power to impose tariffs solely in Congress,&#8221; the Cato brief asserts.
They argue that the IEEPA was meant to &#8220;limit,&#8221; not expand, executive power, citing legal doctrines that limit presidential authority without clear congressional approval.
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/tech/25/07/46334695/mark-zuckerberg-once-revealed-that-getting-into-harvard-made-his-mom-and-dad-prouder-than-building-f" target="_blank" rel="noreferrer noopener">Mark Zuckerberg Once Revealed That Getting Into Harvard Made His Mom And Dad Prouder Than Building Facebook —Spills The Beans On Why No One Talked To Him At His First Class</a>
Why It Matters: This development comes after a federal appeals court&nbsp;allowed Trump&#8217;s tariffs to <a href="https://www.benzinga.com/news/legal/25/06/45877448/appeals-court-allows-trumps-tariffs-to-remain-in-effect-while-it-reviews-the-lower-courts-decision">remain in effect</a>&nbsp;while reviewing the lower court decisions that blocked the duties on constitutional grounds. The&nbsp;U.S. Court of Appeals for&nbsp;the Federal Circuit granted a temporary stay, preserving Trump&#8217;s &#8220;Liberation Day&#8221; tariffs on most trading partners and separate duties on Canada, China, and Mexico.
Meanwhile, Treasury Secretary Scott Bessent has&nbsp;cautioned that countries failing to <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46269036/scott-bessent-says-tariff-rates-set-to-boomerang-back-in-august-for-countries-failing-to-strike-a-deal">negotiate a deal </a>with the U.S. will face a return to higher tariff rates&nbsp;from August 1. The 90-day pause on the &#8220;reciprocal&#8221; tariffs, initially declared on April 2 and paused for 90 days a week later, is scheduled to conclude on July 9. Bessent clarified that the new effective date does not represent a new deadline or an extension of the original timeline.
On the other hand, billionaire investor Ray Dalio&nbsp;warned that Trump&#8217;s latest <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46338641/ray-dalio-says-trumps-tariffs-are-theoretical-warns-they-may-not-bring-manufacturing-back-to-us">round of tariffs</a> could deepen &#8220;stagflation&#8221; and may never deliver on promises to revive U.S. factory floors.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/economic-data/25/07/46288472/japans-prime-minister-criticizes-trumps-tariff-decision-shigeru-ishiba-calls-move-truly-regrettable">Japan&#8217;s Prime Minister Criticizes Trump&#8217;s Tariff Decision: Shigeru Ishiba Calls Move &#8216;Truly Regrettable&#8217; </a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Cato Institute, NCLA Urge Appeals Court To Reject Trump Tariffs Citing Unauthorized Use Of Statute: Report

Advanced Micro Devices shares are trading higher after HSBC upgraded the stock from Hold to Buy and announced a price target of $200.

In a recent interview,&nbsp;UBS Group AG&nbsp;CEO&nbsp;Sergio Ermotti&nbsp;expressed optimism about the U.S. market, despite ongoing tariff uncertainties.
What Happened:&nbsp;Ermotti, during an <a href="https://www.foxbusiness.com/video/6375447767112">interview </a>with Fox Business on Mornings With Maria, pointed out the &#8220;fantastic opportunity&#8221; in the U.S. due to robust wealth creation. &#8220;This&nbsp;is the reason why we&nbsp;keep investing in our franchise,&#8221; he said. Despite short-term uncertainties, Ermotti remains confident that the U.S.&nbsp;will continue to be a&nbsp;lucrative investment destination.
Ermotti highlighted the need for certainty to drive investment and mitigate risk. He believes that once a decision on tariffs is reached, it will lead to a &#8220;new start.&#8221;
Over the past few years, Ermotti has noticed a growing demand for diversification, with the U.S. being the reference economy for investment. He cited&nbsp;the liquidity and depth of&nbsp;liquidity in the U.S. as unmatched.
Ermotti also touched on the impact of regulatory adjustments post the financial crisis, expressing UBS&#8217;s support for a more accommodating regulatory environment. While welcoming easier regulation, Ermotti noted that the current uncertainty is hindering deal execution. However, he&nbsp;signaled that full certainty on&nbsp;tariffs would enhance the&nbsp;U.S. investing environment.&nbsp;
The UBS CEO concluded by expressing confidence in the U.S., stating that the role of the dollar and the U.S. capital markets will likely continue to be leading ones for the foreseeable future.
SEE ALSO:&nbsp;<a href="https://benzinga.com/crypto/cryptocurrency/25/07/46327959/xrp-spikes-3-is-a-breakout-imminent" target="_blank" rel="noreferrer noopener">XRP Spikes 3%: Is A Breakout Imminent? &#8211; Benzinga</a>
Why It Matters: The U.S. market has been under the cloud of tariff uncertainties, as outlined by&nbsp;<a href="https://www.benzinga.com/news/politics/25/07/46313013/trumps-tariff-letters-spark-high-level-of-uncertainity-and-volatility-says-economist-mohamed-el-erian">senior economist </a>Mohamed El-Erian. The Trump administration&#8217;s tariff letters have sparked a high level of uncertainty and volatility, leading to a wait-and-see approach by businesses and investors.
Furthermore,&nbsp;<a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46212534/if-trump-stays-wedded-to-low-rates-idea-us-risks-a-turkey-style-inflation-horror-show-economist-justin-wolfers-warns">Economist Justin Wolfers</a>&nbsp;has warned that President Donald Trump&#8216;s fixation on low interest rates could set the U.S. on a path similar to the inflation crisis that has gripped Turkey.
Despite these challenges, Ermotti&#8217;s confidence in the long-term prospects of the U.S. market reflects the continued appeal of the country as a top investment destination.
Following a knee-jerk reaction upon the announcement of Liberation Day tariffs, the stock markets have now stabilized with the NASDAQ and S&amp;P 500 recording a 4.21% and 3.72% rise, respectively, over the past month.
Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) and Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) climbed 4.13% and 3.47%, respectively, over the last 30 days. 
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/topics/25/07/46298465/joe-rogan-says-most-americans-dont-want-manufacturing-jobs-but-the-problem-is-that-for-some-doing-the" target="_blank" rel="noreferrer noopener">Joe Rogan Says Most Americans Don&#8217;t Want Manufacturing Jobs But The &#8216;Problem&#8217; Is That For Some Doing Them Now, &#8216;It&#8217;s Their Entire Identity&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

UBS CEO Sees 'Fantastic Opportunity' In US Despite Short-Term Tariff Uncertainty, Suggests Secular Trends Remain 'Intact'

Contracts

OSIS

OSI Systems Receives $34M Contract By International Customer For Cargo And Vehicle Inspection Systems

PainReform Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>), today announced, through its pharmaceutical division, the signing of a strategic investment agreement with LayerBio Inc., a privately held Boston biotechnology company developing proprietary, long-acting, non-opiate treatments for ophthalmic surgery.
This agreement marks PainReform's plan to strategically expand into ophthalmology through the addition of a new drug delivery platform to its specialty pharma, non-opiate pain management pipeline. While the Company continues to advance its lead candidate, PRF-110, for the treatment of post-operative pain in general surgery, this strategic investment introduces a distinct and complementary technology targeting the high-volume cataract surgery market.
Under the terms of the agreement, PainReform will receive a majority equity stake in LayerBio as well as a majority position on LayerBio's board in consideration for an investment based on the successful achievement of milestones of an aggregate amount of $3 million. LayerBio has agreed that it will use the proceeds from PainReform solely for funding a planned Phase II clinical trial of OcuRing-K under an FDA approved protocol. PainReform&nbsp;shall make an initial investment of $600,000 upon closing and the remainder will be provided in tranches, conditioned on the successful achievement of key development milestones. The management of LayerBio will continue to lead product development and operations, with strategic oversight and monitoring provided by PainReform.
The transaction is expected to close by the end of July 2025, subject to customary closing conditions.
 &nbsp;

PRFX

PainReform Signs Strategic Investment Agreement With LayerBio To Expand Non-Opiate Pain Management Pipeline Into Opthamology

General

AMOD

Alpha Modus Receives Confirmation Of Listing Transfer To Nasdaq Capital Market

<a href="https://www.globenewswire.com/Tracker?data=UYrK6KC-GehWNRQ5AKT8PmMHCg6xJFC8xs67ybh0WhiUoJyrgdWiOmysHbKVJr5YkIQVxAbPNVetLEE0gTbYKpI3tUdb58wTAjzlvIKwSLYsHWlHhH_pEpJr0DKAUeEwHzPIApVKcmhCdnVm-TpEQEX_nHE1i5Ug7vQ_agc7gHHysoWzQuiNmx257hbTDS5FVFi5XXwFnTNVeO0CNIfX_vaj9N_9WMvgnHigiCYF0m1HKN3jroQwEOpz3ZSSjEYZuHaVk2AOlDBJ9hEyPo7-XydRStKj0nCU17BBeCpffp8OtLFQFXiLoXjYQcl5ZFZ1gFfLy6preJomfuOftIrgyFrfAzwLMNMkX-fBT1w_Vs4HNikpauKLaBfq6TJI4GmRjpNGyeK6TI-3mvF_TcQxwQ==">Reliance Global Group, Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) ("Reliance," "we," "us," "our" or the "Company") today announced that it has repaid approximately $5.55 million, or approximately 50% of its long term debt, a strategic action that reduces its leverage, strengthens its balance sheet, and enhances financial flexibility. The repayments were funded through proceeds from the recently announced asset sale of Fortman Insurance Services, a wholly owned subsidiary, which generated $5.0 million in cash for the Company, with the remainder coming from the release of cash collateral held in our restricted cash accounts. As a result, annual principal, interest and service fee payments are expected to decline from approximately $2.95 million to $1.1 million — a reduction of over $1.8 million, or 61%.

Financing

RELI

Reliance Global Repays $5.55M In Debt Following Asset Sale, Cutting Annual Payments By 61%

Data shows excretion of codeine in fingerprint sweat
INBS' System is viable option for non-invasive diagnostic testing
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that it will present its Pharmacokinetic ("PK") study data at the Association for Diagnostics and Laboratory Medicine ("ADLM") 2025 Clinical Lab Expo, taking place July 27–31 in Chicago, Illinois.
The PK study collected human fingerprint sweat specimens for laboratory analysis and used INBS's Intelligent Fingerprinting Drug Screening System (the "System"), a portable, non-invasive system that screens for drugs of abuse via sweat from the fingertips. Study data showed that fingerprint sweat mirrors the rate and extent of codeine found in blood and saliva, making it a strong indicator of codeine ingestion. Statistical comparisons made at the 95% confidence level demonstrated that fingerprint sweat provides a reliable sample matrix for drug detection, with quantitative pharmacokinetic data closely aligning with blood-based results.

Biotech

Intelligent Bio Solutions Inc. - Common Stock

INBS

Intelligent Bio Solutions Study Confirms Codeine Detection In Fingerprint Sweat, Validating Non-Invasive Drug Screening System

Stock Split

GORV

Lazydays Announces 1-For-30 Reverse Stock Split

Goldman Sachs analyst James Schneider initiates coverage on Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Neutral rating and announces Price Target of $140.

Comments

AdvisorShares Trust AdvisorShares Pure US Cannabis ETF

Actualités

Dernières nouvelles pour AdvisorShares Trust AdvisorShares Pure US Cannabis ETF (ARCA:MSOS)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL